Resmed (RMD) Stock Research

Friday

ResMed price target raised by $10 at RBC Capital

Aug 7, 8:27 AM

ResMed price target lowered by $4 at Baird, here's why

Aug 7, 7:59 AM

ResMed price target lowered by $10 at Wells Fargo, here's why

Aug 7, 7:18 AM

ResMed price target lowered by $5 at KeyBanc, here's why

Aug 7, 6:27 AM

Thursday

Closing Bell Movers: Doximity soars after quarterly report

+17

Aug 6, 6:46 PM

ResMed increases quarterly dividend 10% to 66c per quarter

Aug 6, 4:27 PM

ResMed reports Q4 EPS $2.95, consensus $2.89

Aug 6, 4:27 PM

Over a week ago

SpaceX initiated, Lululemon downgraded: Wall Street's top analyst calls

+16

Jul 16, 9:33 AM

ResMed just downgraded at RBC Capital, here's why

Jul 16, 6:26 AM

ResMed price target lowered by $15 at Mizuho, here's why

Jul 15, 7:26 AM

ResMed just downgraded at Citi, here's why

Jul 12, 7:19 PM

ResMed price target lowered by $15 at Jefferies, here's why

Jul 10, 9:06 AM

ResMed price target lowered by $45 at RBC Capital, here's why

Jul 8, 7:43 AM

ResMed price target lowered by $2 at Wells Fargo, here's why

Jul 8, 6:21 AM

Frazier to acquire MatrixCare from ResMed, terms not disclosed

Jul 7, 5:07 PM

ResMed to sell MatrixCare business to Frazier Healthcare, terms undisclosed

Jul 7, 4:33 PM

ResMed added to APAC Conviction List at Goldman Sachs

Jul 1, 7:13 PM

ResMed price target lowered by $24 at KeyBanc, here's why

Jun 22, 5:44 AM

What You Missed On Wall Street On Wednesday

+27

Jun 17, 4:09 PM

Midday Fly By: Jabil reports 'beat and raise,' Diana Shipping ups Genco offer

+23

Jun 17, 11:55 AM

Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls

+23

Jun 17, 9:47 AM

Video: SpaceX eyes fourth straight day of gains

Jun 17, 9:05 AM

ResMed just downgraded at Morgan Stanley, here's why

Jun 17, 5:34 AM

ResMed price target lowered by $70 at Citi, here's why

Jun 15, 6:17 AM

Early notable gainers among liquid option names on June 3rd

Jun 3, 9:55 AM

Global Market Leadership in Sleep & Respiratory Care: Resmed holds a dominant global market share in sleep apnea devices (CPAP, masks) and related respiratory care products, establishing it as a go-to provider.

Robust Research & Development Investment: Consistent and significant investment in R&D fuels a strong pipeline of innovative products, advanced algorithms, and differentiated solutions for patient care.

Extensive Intellectual Property Portfolio: A comprehensive array of patents protects its core technologies, product designs, and software, creating substantial barriers to entry for potential competitors.

Intense Competition Pressure: The medical device market for sleep apnea and respiratory care is highly competitive, with established players and new entrants potentially eroding market share or pricing power.

Regulatory Compliance Burden: Resmed operates in a heavily regulated industry, requiring extensive approvals, compliance with evolving standards (e.g., FDA, GDPR), and potential for recalls or fines.

Supply Chain Vulnerabilities: Reliance on a global supply chain for components (e.g., semiconductors) and manufacturing exposes Resmed to disruptions, cost increases, and delays.

Charts

Regulatory Compliance Burden: Resmed operates in a heavily regulated industry, requiring extensive approvals, compliance with evolving standards (e.g., FDA, GDPR), and potential for recalls or fines.

Supply Chain Vulnerabilities: Reliance on a global supply chain for components (e.g., semiconductors) and manufacturing exposes Resmed to disruptions, cost increases, and delays.

Friday

ResMed price target raised by $10 at RBC Capital

Aug 7, 8:27 AM

ResMed price target lowered by $4 at Baird, here's why

Aug 7, 7:59 AM

ResMed price target lowered by $10 at Wells Fargo, here's why

Aug 7, 7:18 AM

ResMed price target lowered by $5 at KeyBanc, here's why

Aug 7, 6:27 AM

Thursday

Closing Bell Movers: Doximity soars after quarterly report

+17

Aug 6, 6:46 PM

ResMed increases quarterly dividend 10% to 66c per quarter

Aug 6, 4:27 PM

ResMed reports Q4 EPS $2.95, consensus $2.89

Aug 6, 4:27 PM

Over a week ago

SpaceX initiated, Lululemon downgraded: Wall Street's top analyst calls

+16

Jul 16, 9:33 AM

ResMed just downgraded at RBC Capital, here's why

Jul 16, 6:26 AM

ResMed price target lowered by $15 at Mizuho, here's why

Jul 15, 7:26 AM

ResMed just downgraded at Citi, here's why

Jul 12, 7:19 PM

ResMed price target lowered by $15 at Jefferies, here's why

Jul 10, 9:06 AM

ResMed price target lowered by $45 at RBC Capital, here's why

Jul 8, 7:43 AM

ResMed price target lowered by $2 at Wells Fargo, here's why

Jul 8, 6:21 AM

Frazier to acquire MatrixCare from ResMed, terms not disclosed

Jul 7, 5:07 PM

ResMed to sell MatrixCare business to Frazier Healthcare, terms undisclosed

Jul 7, 4:33 PM

ResMed added to APAC Conviction List at Goldman Sachs

Jul 1, 7:13 PM

ResMed price target lowered by $24 at KeyBanc, here's why

Jun 22, 5:44 AM

What You Missed On Wall Street On Wednesday

+27

Jun 17, 4:09 PM

Midday Fly By: Jabil reports 'beat and raise,' Diana Shipping ups Genco offer

+23

Jun 17, 11:55 AM

Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls

+23

Jun 17, 9:47 AM

Video: SpaceX eyes fourth straight day of gains

Jun 17, 9:05 AM

ResMed just downgraded at Morgan Stanley, here's why

Jun 17, 5:34 AM

ResMed price target lowered by $70 at Citi, here's why

Jun 15, 6:17 AM

Early notable gainers among liquid option names on June 3rd

Jun 3, 9:55 AM

Company News

Charts